COMMUNIQUÉS West-GlobeNewswire
-
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
18/06/2026 -
SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets
18/06/2026 -
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
18/06/2026 -
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
18/06/2026 -
Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring
18/06/2026 -
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
18/06/2026 -
Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”
18/06/2026 -
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
18/06/2026 -
COUR Pharma Announces Closing of $50 Million Series B
18/06/2026 -
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
18/06/2026 -
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
18/06/2026 -
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
18/06/2026 -
Court victory paves the way for Curium’s plans to provide targeted radioligand therapy to U.S. patients with GEP-NETs
18/06/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
18/06/2026 -
Hi*Ball Energy Arrives in the UK, Leading a New Wave of Clean Energy
18/06/2026 -
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
18/06/2026 -
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
18/06/2026 -
Zelluna ASA: Disclosure of large shareholding
18/06/2026 -
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
18/06/2026
Pages